LNSRHealthcare · Medical DevicesThe 2 Wall Street analysts covering LENSAR, Inc. hold a median 12-month price target of $12 — +32.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores LENSAR, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (91): Sales and profits are climbing, and climbing faster than before.
Momentum (12): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LNSR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +32.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | BTIG | Maintains | Buy | $9.00 → $10 |
| 13 Aug 2026 | BTIG | Maintains | Buy | $7.00 → $9.00 |
| 18 Mar 2026 | BTIG | Upgrade | Buy | $10 |
| 18 Mar 2026 | BTIG | Upgrade | Buy | — |
| 24 Mar 2025 | Lake Street | Downgrade | Hold | — |
| 28 Feb 2025 | Lake Street | Maintains | Buy | — |
| 19 Mar 2024 | Lake Street | Initiates | Buy | — |
| 22 Nov 2021 | BTIG | Initiates | Buy | — |
| 24 Feb 2021 | SVB Leerink | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LNSR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 56% of US stocks
Cheaper than 15% of US stocks
Cheaper than 80% of US stocks
Higher than 68% of US stocks
Higher than 59% of US stocks
Higher than 69% of US stocks
Higher than 97% of US stocks
Higher than 99% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LENSAR, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
LENSAR reported 18% revenue growth for the second quarter of 2026, continuing its commercial rebuilding efforts after the termination of its proposed merger with Alcon near the end of the first quarter.
Why it matters — A LNSR watcher would care because the company is demonstrating revenue growth and recovering commercial momentum after a major deal fell through earlier this year.
Seeking Alpha published the transcript of LENSAR, Inc.'s Q2 2026 earnings call. The item is the full transcript of the company's quarterly earnings discussion.
Why it matters — A LENSAR watcher would want to review the earnings call transcript for the company's Q2 2026 financial details and management commentary.
LENSAR reported its second quarter 2026 financial results and provided a business update. The company recorded 10 ALLY Robotic Cataract Laser System placements in the quarter, with a backlog of 13 ALLY systems as of June 30, 2026, and second-quarter recurring revenue of $13.7 million. Its total installed base rose to 445 systems, supported by a 30% increase in ALLY placements.
Why it matters — LENSAR watchers would care because the results show growth in ALLY system placements, a rising installed base, and higher recurring revenue, all of which reflect the company's commercial momentum.
The 2 Wall Street analysts covering LENSAR, Inc. have a median 12-month price target of $12, with estimates ranging from $10 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering LENSAR, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENSAR, Inc. 60 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, LENSAR, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +32.3% from the last close, and Ticker Nerd's factor model ranks LENSAR, Inc. 60 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LENSAR, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNSR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $13 over the next 12 months.
LENSAR, Inc. returned -30.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Lensar Inc. is renowned for its advancement in femtosecond laser technology, specifically designed for cataract surgery.
The most recent item we track (MarketBeat, 13 Aug 2026): "LENSAR Q2 Earnings Call Highlights". LENSAR reported 18% revenue growth for the second quarter of 2026, continuing its commercial rebuilding efforts after the termination of its proposed merger with Alcon near the end of the first quarter.
Lensar Inc. is renowned for its advancement in femtosecond laser technology, specifically designed for cataract surgery. As a medical technology company, Lensar focuses predominantly on offering innovative solutions that enhance the precision and effectiveness of cataract surgery procedures. Its flagship product, the Lensar Laser System, is engineered to provide surgeons with superior imaging and laser guidance to perform precise cataract surgeries, thereby improving surgical outcomes and patient safety. Lensar operates at the intersection of healthcare and technology, influencing the ophthalmology sector significantly. By providing state-of-the-art laser systems, the company plays a critical role in advancing surgical standards and patient care in the rapidly growing field of eye health. Headquartered in Orlando, Florida, Lensar continues to contribute to medical technology through continuous research and development, reinforcing its position as a key player in promoting cutting-edge surgical solutions globally.
CEO Mr. Nicholas T. Curtis · 150 employees · United States · https://www.lensar.com